Merck’s Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 for Patients with MSI-H Colorectal Cancer #ASCO20

Shots:

• The P-III KEYNOTE-177 study involves assessing of Keytruda (200mg IV on Day 1 of each 3wks. cycle for up to 35cycles) vs SOC CT (mFOLFOX6 or FOLFIRI, with/ out bevacizumab or cetuximabin) in 307 patients with 1L MSI-H or dMMR metastatic colorectal cancer
• Results: PFS (16.5 vs 8.2mos.); @2yrs. PFS rate (48% vs 19%); ORR (43.8% vs 33.1%); CR (11.1% vs 3.9%); PR (32.7% vs 29.2%); durable responses lasting at least 2yrs. (83% vs 35%), presented on May 31, 2020 at ASCO20
• Additionally, Merck also presented data from two studies (KEYNOTE-524/Study 116 and KEYNOTE-146/Study 111) evaluating Keytruda + Lenvima in patients with unresectable HCC with no prior systemic therapy and with metastatic ccRCC who progressed following immune checkpoint inhibitor therapy, respectively. The studies demonstrated a meaningful improvement in ORR

Click here ­to­ read full press release/ article | Ref: Merck | Image: Merck